| ViroPharma's Phase III transplant drug study fails endpoint - Pharmaceutical Business Review |
|
|
... III trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant patients did not achieve its primary endpoint. ... |